MTOR and gastrointestinal stromal tumor: A study involving 108 GIST patients revealed that mTOR signalling was highly activated in both PDGFRA‐mutant and wild‐type cases, further supporting the potential therapeutic value of mTOR inhibitors for primary‐resistant GISTs [83].